These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9682385)

  • 21. Novel ISCOMs from Quillaja brasiliensis saponins induce mucosal and systemic antibody production, T-cell responses and improved antigen uptake.
    Cibulski SP; Mourglia-Ettlin G; Teixeira TF; Quirici L; Roehe PM; Ferreira F; Silveira F
    Vaccine; 2016 Feb; 34(9):1162-71. PubMed ID: 26826546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antigenicity and immunogenicity of experimental equine influenza ISCOM vaccines.
    Mumford JA; Jessett D; Dunleavy U; Wood J; Hannant D; Sundquist B; Cook RF
    Vaccine; 1994 Jul; 12(9):857-63. PubMed ID: 7975864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines.
    Ghendon Y; Markushin S; Krivtsov G; Akopova I
    Arch Virol; 2008; 153(5):831-7. PubMed ID: 18297235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ISCOMs: an adjuvant with multiple functions.
    Sjölander A; Cox JC; Barr IG
    J Leukoc Biol; 1998 Dec; 64(6):713-23. PubMed ID: 9850152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IgG subclass response and protection against challenge following immunisation of mice with various influenza A vaccines.
    Ben-Ahmeida ET; Potter CW; Gregoriadis G; Adithan C; Jennings R
    J Med Microbiol; 1994 Apr; 40(4):261-9. PubMed ID: 8151677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM matrix.
    Rönnberg B; Fekadu M; Morein B
    Vaccine; 1995 Oct; 13(14):1375-82. PubMed ID: 8585296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CpG-mediated augmentation of CD8+ T-cell responses in mice is attenuated by a water-in-oil emulsion (Montanide ISA-51) but enhanced by an oil-in-water emulsion (IDRI SE).
    Makinen SR; Zhu Q; Davis HL; Weeratna RD
    Int Immunol; 2016 Sep; 28(9):453-61. PubMed ID: 27055469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative antibody responses and protection in mice immunised by oral or parenteral routes with influenza virus subunit antigens in aqueous form or incorporated into ISCOMs.
    Ghazi HO; Potter CW; Smith TL; Jennings R
    J Med Microbiol; 1995 Jan; 42(1):53-61. PubMed ID: 7739026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvants for pandemic influenza vaccines.
    Atmar RL; Keitel WA
    Curr Top Microbiol Immunol; 2009; 333():323-44. PubMed ID: 19768413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of antigen-presenting cells and interleukin-12 in the priming of antigen-specific CD4+ T cells by immune stimulating complexes.
    Robson NC; Beacock-Sharp H; Donachie AM; Mowat AM
    Immunology; 2003 Sep; 110(1):95-104. PubMed ID: 12941146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Involvement of interleukin-2 and interferon-gamma in the immune response induced by influenza virus iscoms.
    Villacres-Eriksson M; Bergström-Mollaoglu M; Kåberg H; Morein B
    Scand J Immunol; 1992 Sep; 36(3):421-6. PubMed ID: 1519036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses.
    Hu KF; Elvander M; Merza M; Akerblom L; Brandenburg A; Morein B
    Clin Exp Immunol; 1998 Aug; 113(2):235-43. PubMed ID: 9717973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune responses in mice induced by HSV-1 glycoproteins presented with ISCOMs or NISV delivery systems.
    Hassan Y; Brewer JM; Alexander J; Jennings R
    Vaccine; 1996 Dec; 14(17-18):1581-9. PubMed ID: 9032885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Internalization of iscom-borne antigens and presentation under MHC class I or class II restriction.
    Villacres MC; Behboudi S; Nikkila T; Lovgren-Bengtsson K; Morein B
    Cell Immunol; 1998 Apr; 185(1):30-8. PubMed ID: 9636680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses.
    Smith RE; Donachie AM; Grdic D; Lycke N; Mowat AM
    J Immunol; 1999 May; 162(9):5536-46. PubMed ID: 10228035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel oil-in-water emulsion as a potential adjuvant for influenza vaccine: development, characterization, stability and in vivo evaluation.
    Deng J; Cai W; Jin F
    Int J Pharm; 2014 Jul; 468(1-2):187-95. PubMed ID: 24704309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of adjuvants for immune potentiating properties and side effects in mice.
    Leenaars PP; Hendriksen CF; Koedam MA; Claassen I; Claassen E
    Vet Immunol Immunopathol; 1995 Sep; 48(1-2):123-38. PubMed ID: 8533308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines.
    Rimmelzwaan GF; Baars M; van Beek R; van Amerongen G; Lövgren-Bengtsson K; Claas EC; Osterhaus AD
    J Gen Virol; 1997 Apr; 78 ( Pt 4)():757-65. PubMed ID: 9129647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses.
    Sjölander A; van't Land B; Lövgren Bengtsson K
    Cell Immunol; 1997 Apr; 177(1):69-76. PubMed ID: 9140097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral vaccination with immune stimulating complexes.
    Mowat AM; Smith RE; Donachie AM; Furrie E; Grdic D; Lycke N
    Immunol Lett; 1999 Jan; 65(1-2):133-40. PubMed ID: 10065639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.